Low and high affinity dopamine transporter inhibitors block dopamine uptake within 5 sec of intravenous injection

Neuroscience

Volumn 182, Issue , 2011, Pages 125-132

  Yorgason, J T ^a   Jones, S R ^a   Espana R A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cocaine; Methylphenidate; Nomifensine; Nucleus accumbens; Rat; Voltammetry

Indexed keywords

2BETA PROPANOYL 3BETA (4 TOLYL)TROPANE; 3BETA (2 NAPHTHYL) 2BETA PROPIONYLTROPANE; COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; DOPAMINE TRANSPORTER INHIBITOR; DOPAMINE UPTAKE INHIBITOR; METHYLPHENIDATE; NOMIFENSINE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG BINDING; DRUG RESPONSE; EVOKED RESPONSE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING, COMPETITIVE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; INJECTIONS, INTRAVENOUS; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; TIME FACTORS;

EID: 79955482537     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.03.017     Document Type: Article

References (68)

1. Abreu M.E., Bigelow G.E., Fleisher L., Walsh S.L. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) 2001, 154:76-84.
2. Ahmed S.H., Lin D., Koob G.F., Parsons L.H. Escalation of cocaine self-administration does not depend on altered cocaine-induced nucleus accumbens dopamine levels. J Neurochem 2003, 86:102-113.
3. Bennett B.A., Wichems C.H., Hollingsworth C.K., Davies H.M., Thornley C., Sexton T., Childers S.R. Novel 2-substituted cocaine analogs: uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain. J Pharmacol Exp Ther 1995, 272:1176-1186.
4. Batsche K., Granoff M.I., Wang R.Y. 5-HT3 receptor antagonists fail to block the suppressant effect of cocaine on the firing rate of A10 dopamine neurons in the rat. Brain Res 1992, 592:273-277.
5. Bergman J., Madras B.K., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989, 251:150-155.
6. Busto U., Sellers E.M. Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. Clin Pharmacokinet 1986, 11:144-153.
7. Dutta A.K., Coffey L.L., Reith M.E. Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine for the dopamine transporter: effect of different aromatic substitutions on their affinity and selectivity. J Med Chem 1997, 40:35-43.
8. Einhorn L.C., Johansen P.A., White F.J. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J Neurosci 1988, 8:100-112.
9. España R.A., Oleson E.B., Locke J.L., Brookshire B.R., Roberts D.C.S., Jones S.R. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci 2010, 31:336-348.
10. España R.A., Roberts D.C.S., Jones S.R. Short-acting cocaine and long-acting GBR-12909 both elicit rapid dopamine uptake inhibition following intravenous delivery. Neuroscience 2008, 155:250-257.
11. España R.A., Melchior J.R., Roberts D.C.S., Jones S.R. Hypocretin 1/Orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology 2010, 214:415-426.
12. Evans S.M., Cone E.J., Henningfield J.E. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 1996, 279:1345-1356.
13. Ferris M.J., Mateo Y., Roberts D.C., Jones S.R. Cocaine-insensitive dopamine transporters with intact substrate transport produced by self-administration. Biol Psychiatry 2011, 69:201-207.
14. Fowler J.S., Volkow N.D., Logan J., Gatley S.J., Pappas N., King P., Ding Y.S., Wang G.J. Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. Synapse 1998, 28:111-116.
15. Froimowitz M., Gu Y., Dakin L.A., Nagafuji P.M., Kelley C.J., Parrish D., Deschamps J.R., Janowsky A. Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem 2007, 50:219-232.
16. Froimowitz M., Wu K.M., Moussa A., Haidar R.M., Jurayj J., George C., Gardner E.L. Slow-onset, long-duration 3-(3',4'-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse. J Med Chem 2000, 43:4981-4992.
17. Gardner E.L., Liu X., Paredes W., Giordano A., Spector J., Lepore M., Wu K.M., Froimowitz M. A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction. Neuropharmacology 2006, 51:993-1003.
18. Gatley S.J., Pan D., Chen R., Chaturvedi G., Ding Y.S. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 1996, 58:231-239.
19. Glowa J.R., Fantegrossi W.E., Lewis D.B., Matecka D., Rice K.C., Rothman R.B. Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909. J Med Chem 1996, 39:4689-4691.
20. Gossop M., Griffiths P., Powis B., Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict 1992, 87:1527-1536.
21. Gossop M., Griffiths P., Powis B., Strang J. Cocaine: patterns of use, route of administration, and severity of dependence. Br J Psychiatry 1994, 164:660-664.
22. Greco P.G., Garris P.A. In vivo interaction of cocaine with the dopamine transporter as measured by voltammetry. Eur J Pharmacol 2003, 479:117-125.
23. Hatsukami D.K., Fischman M.W. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality?. JAMA 1996, 276:1580-1588.
24. Hemby S.E., Co C., Koves T.R., Smith J.E., Dworkin S.I. Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat. Psychopharmacology (Berl) 1997, 133:7-16.
25. Henningfield J.E., Keenan R.M. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993, 61:743-750.
26. Hinerth M.A., Collins H.A., Baniecki M., Hanson R.N., Waszczak B.L. Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons. Synapse 2000, 38:305-312.
27. Howell L.L., Byrd L.D. Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey. J Pharmacol Exp Ther 1991, 258:178-185.
28. John C.E., Jones S.R. Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology 2007, 52:1596-1605.
29. Jones S.R., Garris P.A., Kilts C.D., Wightman R.M. Comparison of dopamine uptake in the basolateral amygdaloid nucleus, caudate-putamen, and nucleus accumbens of the rat. J Neurochem 1995, 64:2581-2589.
30. Katz J.L., Izenwasser S., Terry P. Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology (Berl) 2000, 148:90-98.
31. Kiyatkin E.A., Kiyatkin D.E., Rebec G.V. Phasic inhibition of dopamine uptake in nucleus accumbens induced by intravenous cocaine in freely behaving rats. Neuroscience 2000, 98:729-741.
32. Kollins S.H., Rush C.R., Pazzaglia P.J., Ali J.A. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 1998, 6:367-374.
33. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science 1988, 242:715-723.
34. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997, 278:52-58.
35. Kuczenski R., Segal D.S., Aizenstein M.L. Amphetamine, cocaine, and fencamfamine-relationship between locomotor and stereotypy response profiles and caudate and accumbens-dopamine dynamics. J Neurosci 1991, 11:2703-2712.
36. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991, 14:299-302.
37. Lile J.A., Morgan D., Birmingham A.M., Wang Z., Woolverton W.L., Davies H.M., Nader M.A. The reinforcing efficacy of the dopamine reuptake inhibitor 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT) as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys. J Pharmacol Exp Ther 2002, 303:640-648.
38. Liu Y., Roberts D.C., Morgan D. Sensitization of the reinforcing effects of self-administered cocaine in rats: effects of dose and intravenous injection speed. Eur J Neurosci 2005, 22:195-200.
39. Mateo Y., Budygin E.A., Morgan D., Roberts D.C.S., Jones S.R. Fast onset of dopamine uptake inhibition by intravenous cocaine. Eur J Neurosci 2004, 20:2838-2842.
40. Newman A.H., Kulkarni S. Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic-a focus on analogues of benztropine and rimcazole. Med Res Rev 2002, 22:429-464.
41. Oldendorf W.H. Some relationships between addiction and drug delivery to the brain. NIDA Res Monogr 1992, 120:13-25.
42. Pettit H.O., Justice J.B. Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. Pharmacol Biochem Behav 1989, 34:899-904.
43. Pitts D.K., Marwah J. Cocaine modulation of central monoaminergic neurotransmission. Pharmacol Biochem Behav 1987, 26:453-461.
44. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219-1223.
45. Roberts D.C.S. Self-administration of GBR 12909 on a fixed ratio and progressive ratio schedule in rats. Psychopharmacology (Berl) 1993, 111:202-206.
46. Roberts D.C.S., Corcoran M.E., Fibiger H.C. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 1977, 6:615-620.
47. Roberts D.C.S., Phelan R., Hodges L.M., Hodges M.M., Bennett B., Childers S., Davies H. Self-administration of cocaine analogs by rats. Psychopharmacology (Berl) 1999, 144:389-397.
48. Rothman R.B., Baumann M.H., Prisinzano T.E., Newman A.H. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 2008, 75:2-16.
49. Runyon S.P., Carroll F.I. Dopamine transporter ligands: recent developments and therapeutic potential. Curr Top Med Chem 2006, 6:1825-1843.
50. Samaha A.N., Li Y., Robinson T.E. The rate of intravenous cocaine administration determines susceptibility to sensitization. J Neurosci 2002, 22:3244-3250.
51. Samaha A.N., Mallet N., Ferguson S.M., Gonon F., Robinson T.E. The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. J Neurosci 2004, 24:6362-6370.
52. Samaha A.N., Robinson T.E. Why does the rapid delivery of drugs to the brain promote addiction?. Trends Pharmacol Sci 2005, 26:82-87.
53. Seecof R., Tennant F.S. Subjective perceptions to the intravenous "rush" of heroin and cocaine in opioid addicts. Am J Drug Alcohol Abuse 1986, 12:79-87.
54. Stathis M., Scheffel U., Lever S.Z., Boja J.W., Carroll F.I., Kuhar M.J. Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology (Berl) 1995, 119:376-384.
55. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley J.S., Dewey S., Ashby C., Liebermann J., Hitzemann R. Is methylphenidate like cocaine?. Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995, 52:456-463.
56. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., Vitkun S., Logan J., Gatley S.J., Pappas N., Hitzemann R., Shea C.E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386:827-830.
57. Wakazono Y., Kiyatkin E.A. Electrophysiological evaluation of the time-course of dopamine uptake inhibition induced by intravenous cocaine at a reinforcing dose. Neuroscience 2008, 151:824-835.
58. Wise R.A. Neurobiology of addiction. Curr Opin Neurobiol 1996, 6:243-251.
59. Wise R.A., Newton P., Leeb K., Burnette B., Pocock D., Justice J.B. Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology (Berl) 1995, 120:10-20.
60. Wise R.A., Wang B., You Z.B. Cocaine serves as a peripheral interoceptive conditioned stimulus for central glutamate and dopamine release. PLoS One 2008, 3:e2846.
61. Woolverton W.L., Hecht G.S., Agoston G.E., Katz J.L., Newman A.H. Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology (Berl) 2001, 154:375-382.
62. Woolverton W.L., Johnson K.M. Neurobiology of cocaine abuse. Trends Pharmacol Sci 1992, 13:193-200.
63. Woolverton W.L., Wang Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 2004, 486:251-257.
64. Wu Q., Reith M.E., Wightman R.M., Kawagoe K.T., Garris P.A. Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry. J Neurosci Methods 2001, 112:119-133.
65. Xu L., Kelkar S.V., Lomenzo S.A., Izenwasser S., Katz J.L., Kline R.H., Trudell M.L. Synthesis, dopamine transporter affinity, dopamine uptake inhibition, and locomotor stimulant activity of 2-substituted 3 beta-phenyltropane derivatives. J Med Chem 1997, 40:858-863.
66. Yorgason J.T., España R.A., Jones S.R. Demon voltammetry and analysis software: analysis of cocaine-dopamine transporter interactions using several kinetic measurements. J Neurosci Methods 2011, 10.1016/j.jneumeth.2011.03.001.
67. Zahniser N.R., Larson G.A., Gerhardt G.A. In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors. J Pharmacol Exp Ther 1999, 289:266-277.
68. Zernig G., Giacomuzzi S., Riemer Y., Wakonigg G., Sturm K., Saria A. Intravenous drug injection habits: drug users' self-reports versus researchers' perception. Pharmacology 2003, 68:49-56.